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Management Of Primary Breast Cancer
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The University of Hong Kong
Summary
The current management of primary breast cancer is based on a selective combination approach using surgery of lesser
extent, radiotherapy and systemic therapy. It aims at achieving excellent locoregional control and improved survival with
minimal morbidity. This article describes a rational approach to the management of primary operable breast cancer < 5 cm
in size. Its success is measured by the rates of locoregional recurrence and long-term survival, which would be separately
addressed. A brief discussion would also be made on the management of ductal carcinoma in situ and the follow-up policy
for women after treatment of the primary cancer. (HK Pract 1997; 19: 256-263)
£• x & i* 5 S. *. « T ^ - IL
' & 4t &*& Mattel it & ' & a
r^j.ft-f& °
* ' sLULft. is. <li IL B$. -f S, Jk S. &. II
Introduction
The management of primary
breast cancer has evolved from
radical surgery introduced by William
Stewart Halsted more than a century
ago1 to a selective combination
approach using surgery of lesser
extent, radiotherapy and systemic
therapy. It aims at achieving
excellent locoregional control and
improved survival with minimal
morbidity. This article describes a
rational approach to the management
of pr imary operable breast cancer
< 5 cm in size.
Local control - manage-
ment of the breast
Surgery
Halsted's operation of radical
mastectomy is no longer popular
since modified radical mastectomy of
Patey where the pectoralis major is
preserved offers s i m i l a r local
control.2 The local recurrence rate
of modified radical mastectomy is
similar to that of breast conservation
with wide local excision followed by
intact breast irradiation.3 ,4 Recent
large-scale randomised s tudies also
confirm no difference in survival.5
From the oncological point of
view, a cancer of s m a l l size e.g.
< 3 cm (larger cancer may be suitable
if the breast is of large size), and
* Address for correspondence: Dr K L Cheung, Department of Surgery, Tung Wah Hospital, 12 Po Yan Street, Hong Kong.
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the absence of multifocal disease on
a mammogram are the two most
important preoperative criteria to
recommend breast conservation as an
option of treatment. The location of
the cancer and the size of the breast
are certainly factors that could affect
the cosmetic outcome. Proximity of
the cancer to the nipple-areola
complex does not preclude breast
conservation. Only 10% of
subareolar cancers require excision of
the nipple-areola complex to obtain
adequate margin.6 After wide local
excision, the specimen is carefully
examined. In case of involved or
inadequate margin e.g. < 0.5 cm at
one place, a re-excision should be
considered though some would give
an boost dose of irradiation to the
area concerned. On the other hand,
if the margin is involved or
inadequate in multiple areas, or if
there is lymphovascular permeation,
especially in younger women,
conversion to mastectomy (necessary
in approximately 10% of cases)
should be carried out owing to an
unacceptably high chance of local
recurrence after breast conservation
when these histological factors are
present. Using such strict selection
criteria, a 2.2% local recurrence rate
in 3 years could be achieved.7
Women with cancer failing these
criteria undergo mastectomy. Plastic
reconstruction should be offered.
Methods include simple implant
insertion, pedicled latissimus dorsi
flap with an implant, pedicled or
free transverse rectus abdominis
myocutaneous (TRAM) flap,
depending on the condition of the
skin, previous irradiation, presence
of scars in the donor area and very
importantly the woman's choice.
Subcutaneous mastectomy, preserving
the nipple, with implant insertion is
also a simple and safe option since
no significant difference in local
recurrence rates could be
demonstrated, provided that the
nipple ducts are carefully examined
histologically to ensure absence of
tumour.8 Immediate reconstruction
is favoured since it is associated
with better psychological outcome
but no adverse effect on additional
therapy.
Radiotherapy
The use of intact breast
irradiation after conservative surgery
has been addressed. On the other
hand, in the mastectomy group, the
rate of local recurrence, as defined
by a histologically proven lesion in
or deep to the mastectomy skin
flaps, remained as high as 23% and
mult iple risk factors of flap
recurrence have been identified viz.
poor histological grade, positive
nodal status and lymphovascular
permeation.9 Selective addition of
flap irradiation when these factors
are present has dramatically reduced
the local recurrence rate to around
5%.
Assessment of local control
The success of the management
of the breast is reflected by the
local recurrence rate which should be
less than 10% in 5 years.10 In fact
over 70% of flap recurrence develop
within the first 2 years." Most of
them are manageable by simple
excision with or without
radiotherapy and systemic therapy.
Using strict selection criteria for
breast conservation and jud ic ious
addition of flap i r radiat ion after
mastectomy have virtually eliminated
uncontrollable local recurrence
commonly seen in the old days.
Regional control - manage-
ment of the axilla
The success of the management
of the axilla is reflected by the rate
of regional recurrence, defined by
lymph node recurrence in the
ipsilateral ax i l l a , as wel l as by
treatment related long-term
morbidity. Similarly, an acceptable
regional recurrence rate is less than
10% in 5 years.10 A watch pol icy
previously advocated leads to a
regional recurrence rate of 20% and
has now been dropped by most
centres. Axillary surgery is required
to obtain adequate staging of the
disease since nodal status is an
important prognostic factor and 30%
of cases with no cl inical ly palpable
lymph nodes have h i s to log ica l ly
positive nodes in the axilla. The
regional recurrence rate wou ld be
high if involved lymph nodes are not
treated, either by surgery or
radiotherapy. However one has to
find a balance between regional
control and morbidity due to axillary
surgery. The more extensive the
surgery is, the more accurate the
staging would be but the chance of
nerve injury and lymphoedema is
also higher.
The most popular way of
managing the axilla is ax i l l a ry
dissection which accurately stages
the cancer and carries low morbidity
in experienced hands. The other
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option is axillary lymph node
sampling followed by treatment of
the axilla with either formal
dissection or radiotherapy. Axillary
sampling is completed by performing
excisional biopsy of lymph nodes
in the axilla below the
intercostobrachial nerve. At least 4
lymph nodes subsequently proven
by histology must be obtained to
give a representative sample for
staging.10 Unfortunately the regional
recurrence rate fol lowing this
approach seems higher. There are
centres advocating axi l la ry lymph
node sampling for small invasive
cancer as well as ductal carcinoma
in situ (DCIS). Furthermore a
combination of axillary dissection
and radiotherapy is not advisable
owing to high morbidity.
Management of internal mammary
lymph nodes
Most centres do not recommend
routine biopsy or empirical treatment
of the internal mammary lymph
nodes since only 10% of cancer
which have positive internal
mammary lymph nodes do not have
axil lary lymph node involvement.
And most of these cancers are
med ia l ly si tuated. In centres
practising axillary lymph node
sampling, there might be a place to
carry out internal mammary lymph
node biopsy for medial cancer to
improve staging.
Adjuvant systemic therapy
Fisher's theory emphasizes the
importance of micrometastases in
breast cancer, which in most of the
time, is a systemic disease from the
very beginning.12 Adjuvant systemic
therapy improves the long-term
survival with a 5-15% absolute
reduction in 10-year mortality. It is
indicated whenever the chance of
micrometastases is high. Nodal
status was previously used as the
single most important indicator of
micrometastases. However, survival
analysis showed that women with
small, node positive cancer could
have long life expectancy whi le a
significant proportion of women with
node negative cancer died shortly
from carcinomatosis. To date the
most impor tant independent
prognostic indicators are nodal status
(cancers with 4 nodes involved
behave worse than those wi th
less), histological grade and size of
the cancer. The Nottingham
Prognostic Index (NPI) is a
combination of these factors: NPI =
Size (cm) x 0.2 + histological grade
( 1 - 3 = I- III) + nodal status (1
= no nodes, 2 = 1-3 nodes, 3 =
>4 nodes). The good (NPI <3.4),
moderate and poor (NPI >5.4)
prognostic groups have respectively
29%, 54% and 17% of all women
with primary operable invas ive
cancer and 80%, 42% and 13% 15-
year survival (Table 1 and Figure
1)." S ince a s u r v i v a l of 80% in
the first group is comparable to that
of age-matched women (83%),
adjuvant systemic therapy is not
indicated. All others require
systemic therapy to attain s u r v i v a l
benefit.
Conventionally, premenopausal
women receive chemotherapy wi th
cyclophosphamide. methotrexate and
5-f luorouraci l (CMF) w h i l e
postmenopausal women have
tamoxifen if the cancer is oestrogen
receptor (ER) positive or CMF if it
is ER negative.14 However there is
evidence that the efficacy of CMF,
surgical oophorectomy, r ad ia t ion
menopause or LHRH agonist such as
goserelin in reducing the circulating
oestradial level is the same.15 Their
differences lie in the morb id i ty ,
compliance, ease of application and
cost of the therapy. Therefore,
some centres employ methods other
than CMF as adjuvant systemic
therapy in premenopausal women
with ER positive cancers. Addition
Table 1: Distribution of invasive primary breast cancer according
to the Nottingham Prognostic Index (NPI) in screened
(prevalent round) and unscreened population
NPI
<3.4
3.4 - 5,4
>5.4
Screened
n %
102 76%
27 20%
5 4%
Unscreened
n
470
879
280
29%
54%
17%
259
Primary Breast Cancer
Figure 1: Patient survival according to the Nottingham Prognostic
Index (NPI)
NPI<3.4
20
O 24 48 72 96 120 144 168 192
Months
of an anthracycline to the CMF
regimen may be considered for
women wi th more aggressive
cancers, such as those with more
than 10 lymph nodes involved, only
after serious discussion with the
woman concerned since its long-
term benefit in th i s already poor
prognostic group may be minimal
and the morbidity is certainly higher.
There are controversies on the
durat ion of adjuvant therapy. No
additional benefit has been shown if
chemotherapy is given for more than
6 months. The most popular
regimen therefore includes six 3-
weekly cycles of CMF. On the
other hand, in spite of the long-
term r isk of endometr ia l
hype rp l a s i a and carcinoma for
women taking tamoxifen, tamoxifen
is s t i l l recommended since its
benef ic ia l effect on breast cancer
significantly outweighs its minimal
risk on the uterus. Furthermore,
using high doses of tamoxifen does
not offer extra advantage. Until an
answer comes out from ongoing
randomised trials, the usual
tamoxifen regimen is 20 mg daily for
5 years.
The management algorithm
described is summarised in Figure 2.
Management of ductal
carcinoma in situ
Mastectomy has been the gold
standard in the treatment of DCIS
with minimal local recurrence rates.
With efficacy of breast conservation
clearly demonstrated in invasive
breast cancer, recently there are
increasing numbers of women
undergoing wide local exc i s ion
followed by intact breast irradiation
for DCIS. The selection criteria of
small tumour without demonstrable
mult i focal i ty , as we l l as adequate
his to logica l margins should be
fol lowed. In genera l , a x i l l a r y
surgery is avoided due to the low
incidence of nodal invo lvement .
When the diagnosis of DCIS is
uncertain preoperatively, it is
p robab ly j u s t i f i e d to perform
axillary surgery at the t ime of
mastectomy. On the contrary, if
the cancer is s u i t a b l e for breast
conservation, it would be more
reasonable to wait for the histology
resul ts pr ior to c o n t e m p l a t i n g
axi l la ry surgery via a different
i n c i s i o n . Ad juvan t systemic
therapy is not i n d i c a t e d s ince
DCIS has an excel lent prognos is
after adequate initial treatment.
Follow-up
The main aim of follow-up of
women after treatment of pr imary
breast cancer is to detect and
offer treatment to l o c o r e g i o n a l
recurrence, as well as contralateral
breast cancer, s ince the r i sk of
having a new pr imary increases at
a rate of 1% per year. The follow-
up schedule , therefore , i n v o l v e s
regular physical examination,
general ly at 6-monthly i n t e r v a l
for 5 years since most locoregional
recurrence would have developed
wi th in this per iod, together with
screening mammogram for the
opposite breast or both breas ts
in case of breast conservat ion, at
an interval of 1-2 years (Table 2).
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Table 2: Follow-up algorithm for primary breast cancer
Method
Physical examination
Mammogram
Metastatic screening
Interval
6-monthly for 5 years, then yearly
Yearly for intact breast after irradiation
1-2 years for contralateral breast
Not indicated if asymptomatic
Routine metastatic screening is
not cost-effective since it could only
detect less than 12% of metastases
at the asymptomatic stage, depending
on the nature of tests performed.1 6
Furthermore, at the t ime of
metastases, the median survival is 2
years and the objective of treatment
is to pa l l ia te symptoms and to
maintain the highest possible quality
of l i fe .1 0 The va lue of offering
therapy in the absence of symptoms
is therefore doubtful.
Figure 2: Management algorithm for invasive primary breast cancer
All
Choice of
treatment
I
Wide local
excision*
Intact breast
irradiation
NPI < 3.4
NPI > 3.4
Clinical/Radiological size > 3 cm or
multifocal disease on mammogram
i
Mastectomy*
t
Failed histological criteria
(inadequate margins, lymphovascular permeation)
Flap irradiation for high risk groups
(high grade, positive nodes,
lymphovascular permeation)
No adjuvant systemic therapy
Premenopausal: CMF
Postmenopausal:
ER positive - tamoxifen
ER negative - CMF
* All have axillary dissection.
NPI = Nottingham prognostic index
ER = Oestrogen receptor
CMF = Cyclophosphamide, methotrexate and 5-fluorouracil
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1. Primary breast cancer can be effectively treated with either mastectomy or breast conservation followed
by radiotherapy, the choice of which does not affect the survival.
2. Excellent locoregional control is obtained by using strict selection criteria for breast conservation and
judicious addition of flap irradiation after mastectomy, as well as by carrying out axillary dissection.
3. Women undergoing mastectomy should be offered the choice of breast reconstruction.
4. Adjuvant systemic therapy is indicated when the chance of micrometastases is high, as reflected by the
nodal status, histological grade and size of the primary tumour. Conventional therapy includes chemo-
therapy or tamoxifen depending on the menopausal and oestrogen receptor status.
5. After the initial treatment of the primary cancer, women should be followed up by regular physical ex-
amination and mammogram.
6. Screening of breast cancer by mammogram is proven to produce a significant survival benefit in women
above the age of 50.
Conclusion and future
direction
With more precise patient
selection and choice of treatment,
locoregional recurrence rate has
markedly decreased and
u n c o n t r o l l a b l e gross locoregional
recurrence has essent ia l ly been
abolished. On the other hand, the
outcome of breast cancer treatment
in terms of survival still depends on
the stage of the disease at the time
of diagnosis . This is beau t i fu l ly
reflected by applying the NPI -
only one-fourth of women with
symptomatic primary breast cancer
belong to the good prognostic group
and have su rv iva l comparable to
normal women. With the advent of
breast cancer screening, the
proport ion of good prognost ic
cancers has dramatically increased:
good, moderate and poor prognostic
groups having a d i s t r i b u t i o n of
respect ively 76%, 20% and 4%
(Table 1),17 not to m e n t i o n the
increased proportion of women with
DCIS. Mammographic screening for
women above the age of 50 has been
proven to produce a survival benefit
approaching 40%,18,19 a gain which
is far better than that achieved by
any regimen of adjuvant systemic
therapy for cancers that are
diagnosed at a late stage. The
feasibility of extending the benefit of
screening to younger and other high-
risk women should be explored.
Other ongoing t r i a l s i n c l u d e
studies to optimize treatment for
small invasive cancer or DC1S. Can
radiotherapy and/or a x i l l a r y surgery
be safely avo ided ? No loca l
recurrence was seen in 42 months
after t rea tment of DCIS by wide
local excision alone.20 Early results
of p r imary systemic therapy are
encouraging in increasing the rates of
breast conservat ion 2 1 but whe the r
such therapy w i l l have long-term
surv iva l benefi t needs to be
elucidated. High-dose chemotherapy
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with stem cell support using
autologous bone marrow transplant
has been proposed as adjuvant
therapy for women with very
aggressive cancers. However this is
an expensive treatment with definite
morbidity but unproven long-term
benefit. The results of randomised
control trials must be awaited before
recommending it as a conventional
modality.22 •
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